Export file:


  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text


  • Citation Only
  • Citation and Abstract

Memantine increases NMDA receptor level in the prefrontal cortex but fails to reverse apomorphine-induced conditioned place preference in rats

1 Department of Physiology, School of Laboratory of Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, 4001, South Africa
2 Institute of Academic Anaesthesia, Division of Neuroscience, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
3 School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Studies have shown that inflammation and neurodegeneration may accompany the development of addiction to apomorphine and that the glutamate NMDA receptor antagonist, memantine, may be neuroprotective. The similarity between apomorphine and dopamine with regard to their chemical, pharmacological and toxicological properties provided a basis for investigating the mechanism of action of the former agent. In this study, we investigated whether memantine would suppress apomorphine-seeking behavior in rats subjected to apomorphine-induced place preference conditioning, through modulation of NMDA receptors in the prefrontal cortex. Repeated apomorphine (1 mg/kg) treatment induced conditioned place preference (CPP) and had no significant effect on NMDA receptor levels in the prefrontal cortex. Prior treatment with memantine (5 mg/kg or 10 mg/kg) increased the levels of NMDA receptors in the prefrontal cortex but did not suppress CPP induced by apomorphine. These data give further support to the addictive effect of apomorphine and demonstrate that blockade of NMDA receptors by memantine is unable to suppress apomorphine-seeking behavior.
  Article Metrics

Keywords apomorphine; memantine; conditioned place preference; NMDA receptors

Citation: Ziphozethu Ndlazi, Oualid Abboussi, Musa Mabandla, Willie Daniels. Memantine increases NMDA receptor level in the prefrontal cortex but fails to reverse apomorphine-induced conditioned place preference in rats. AIMS Neuroscience, 2018, 5(4): 211-220. doi: 10.3934/Neuroscience.2018.4.211


  • 1. Montoya ID, Bobes J (2015) Drugs of Abuse and Pharmacotherapies for Substance Use Disorders: An Introduction. Springer Milan, 315–317.
  • 2. Haleem DJ, Ikram H, Haleem MA (2014) Inhibition of apomorphine-induced conditioned place preference in rats co-injected with buspirone: Relationship with serotonin and dopamine in the striatum. Brain Res 1586: 73–82.    
  • 3. Singh N, Pillay V, Choonara YE (2007) Advances in the treatment of Parkinson's disease. Prog Neurobiol 81: 29–44.    
  • 4. Peskind ER, Potkin SG, Pomara N, et al. (2006) Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial. Am J Geriat Psychiat 14: 704–715.
  • 5. Téllez C, Bustamante ML, Toro P, et al. (2006) Addiction to apomorphine: A clinical case‐centred discussion. Addiction 101: 1662–1665.    
  • 6. Papp M (1988) Different effects of short-and long-term treatment with imipramine on the apomorphine-and food-induced place preference conditioning in rats. Pharmacol Biochem Behav 30: 889–893.    
  • 7. Campbell JC, Jeyamohan SB, De LCP, et al. (2014) Place conditioning to apomorphine in rat models of Parkinson's disease: Differences by dose and side-effect expression. Behav Brain Res 275: 114–119.    
  • 8. Sam E, Verbeke N (1995) Free radical scavenging properties of apomorphine enantiomers and dopamine: Possible implication in their mechanism of action in Parkinsonism. J Neural Transm-Parkinson's Dis Dementia Sect 10: 115–127.    
  • 9. El-Bachá RS, Netter P, Minn A (1999) Mechanisms of apomorphine cytoxicity towards rat glioma C6 cells: Protection by bovine serum albumin and formation of apomorphine-protein conjugates. Neurosci Lett 263: 25–28.    
  • 10. Dos SER, Daval J, Koziel V, et al. (2001) Toxic effects of apomorphine on rat cultured neurons and glial C6 cells, and protection with antioxidants. Biochem Pharmacol 61: 73–85.    
  • 11. Kelley AE (2004) Memory and addiction: Shared neural circuitry and molecular mechanisms. Neuron 44: 161–179.    
  • 12. Di CP, Everitt BJ (2001) Dissociable effects of antagonism of NMDA and AMPA/KA receptors in the nucleus accumbens core and shell on cocaine-seeking behavior. Neuropsychopharmacology 25: 341–360.    
  • 13. Chédotal A, Richards LJ (2010) Wiring the brain: The biology of neuronal guidance. Cold Spring Harbor Perspect Biol 2: a001917.
  • 14. Kozela E, Popik P (2002) The effects of NMDA receptor antagonists on acute morphine antinociception in mice. Amino Acids 23: 163–168.
  • 15. Chen SL, Tao PL, Chu CH, et al. (2012) Low-dose memantine attenuated morphine addictive behavior through its anti-inflammation and neurotrophic effects in rats. J Neuroimmune Pharmacol 7: 444–453.    
  • 16. Overton PG, Clark D (1997) Burst firing in midbrain dopaminergic neurons. Brain Res Rev 25: 312–334.    
  • 17. Volkow ND, Fowler JS, Wang GJ, et al. (1993) Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14: 169–177.    
  • 18. Carr GD, Fibiger HC, Phillips AG (1989) Conditioned place preference as a measure of drug reward. Neuropharmacol Basis Reward 41: 143–150.
  • 19. Spyraki C, Fibiger HC, Phillips AG (1982) Dopaminergic substrates of amphetamine-induced place preference conditioning. Brain Res 253: 185–193.    
  • 20. Van dKD, Swerdlow NR, Koob GF (1983) Paradoxical reinforcing properties of apomorphine: Effects of nucleus accumbens and area postrema lesions. Brain Res 259: 111–118.    
  • 21. Lagreze WA, Knorle RM, Feuerstein T (1998) Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. Invest Ophthalmolo Visual Sci 39: 1063–1066.
  • 22. Wise RA, Yokel RA, Dewit H (1976) Both positive reinforcement and conditioned aversion from amphetamine and from apomorphine in rats. Science 191: 1273–1275.
  • 23. Baxter BL, Gluckman MI, Stein L, et al. (1974) Self-injection of apomorphine in the rat: Positive reinforcement by a dopamine receptor stimulant. Pharmacol Biochem Behav 2: 387–391.    
  • 24. Haleem DJ, Hasnat A, Shireen E, et al. (2005) Dopamine and serotonin neurotransmission in the reinforcing effects of alcohol and apomorphine. J Coll Physicians Surg Pak 15: 458–462.
  • 25. Tzschentke TM, Schmidt WJ (2000) Functional relationship among medial prefrontal cortex, nucleus accumbens, and ventral tegmental area in locomotion and reward. Crit Rev Neurobiol 14: 131–142.
  • 26. Chen G, Greengard P, Yan Z (2004) Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex. Proc Natl Acad Sci U. S. A 101: 2596–2600.    
  • 27. Zweifel LS, Argilli E, Bonci A, et al. (2008) Role of NMDA receptors in dopamine neurons for plasticity and addictive behaviors. Neuron 59: 486–496.    
  • 28. Bisaga A, Comer SD, Ward AS, et al. (2001) The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology 157: 1–10.    
  • 29. Popik P, Wrobel M, Bisaga A (2006) Reinstatement of morphine-conditioned reward is blocked by memantine. Neuropsychopharmacology 31: 160–170.    
  • 30. Popik P, Layer RT, Skolnick P (1994) The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H] MK-801 binding to the NMDA receptor complex. Psychopharmacology 114: 672–674.    
  • 31. Williams K, Dichter MA, Molinoff PB (1992) Up-regulation of N-methyl-D-aspartate receptors on cultured cortical neurons after exposure to antagonists. Mol Pharmacol 42: 147–151.
  • 32. Wu PH, Mihic SJ, Liu JF, et al. (1993) Blockade of chronic tolerance to ethanol by the NMDA antagonist, (+)-MK-801. Eur J Pharmacol 231: 157–164.    
  • 33. Parsons CG (2001) NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 429: 71–78.    
  • 34. Kemp JA, Mckernan RM (2002) NMDA receptor pathways as drug targets. Nat Neurosci 5: 1039–1042.    
  • 35. Popik P, Skolnick P (1996) The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol Biochem Behav 53: 791–797.    
  • 36. Jeanblanc J, Coune F, Botia B, et al. (2015) Brain-derived neurotrophic factor mediates the suppression of alcohol self-administration by memantine. Addict Biol 19: 758–769.
  • 37. Uys JD, Lalumiere RT (2008) Glutamate: The new frontier in pharmacotherapy for cocaine addiction. CNS Neurol Disord: Drug Targets 7: 482–491.    
  • 38. Sattler R, Tymianski M (2000) Molecular mechanisms of calcium-dependent excitotoxicity. J Mol Med 78: 3–13.    


Reader Comments

your name: *   your email: *  

© 2018 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved